Despite significant therapeutic advances, the prognosis of patients with heart failure (HF)
remains poor, and current therapeutic approaches are palliative in the sense that they do not …

After the onset of ischemia, cardiac or skeletal muscle undergoes a continuum of molecular,
cellular, and extracellular responses that determine the function and the remodeling of the …

Rationale: Cell-based therapies are a promising intervention for the treatment of heart failure
(HF) secondary to ischemic and nonischemic cardiomyopathy. However, the clinical efficacy …

Cellular therapy for cardiovascular disease heralds an exciting frontier of research.
Mesenchymal stromal cells (MSCs) are present in adult tissues, including bone marrow and …

Based on the increasingly understood regenerative capacity of the human heart and
vascular system, 1 cardiovascular regenerative medicine (CRM) encompasses all potential …

For the treatment of heart failure, a new strategy to improve cardiac function and inhibit
cardiac remodeling needs to be established. Embryonic stem cells (ESCs) and induced …

Intracoronary and intramyocardial stem cell therapy aim at the repair of compromised
myocardium thereby—as a causal treatment—preventing ventricular remodeling and …

Spinal cord injury (SCI) results in loss of nervous tissue and consequently loss of motor and
sensory function. There is no treatment available that restores the injury-induced loss of …

Aims To evaluate the safety profile and efficacy of bone marrow mononuclear cells
(BMMNC) transplantation for ST-segment elevation myocardial infarction (STEMI) by …

To the Editor: We reported the short-term results (6-month follow-up) of a pilot study of the
role of stem cell therapy in ischemic cardiomyopathy (1). We now present the final long-term …